Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants With Recurrent and/or Refractory Melanoma (PRAMETIME-Mel)

Clinical trial NCT06660420 · RECRUITING

Trial details

NCT number: NCT06660420
Sponsor: M.D. Anderson Cancer Center
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Phase 1 Recurrent Melanoma Refractory Melanoma

Start date: 2025-02-25
Primary completion: 2029-12-31
Enrollment: 39

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.